A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer
The study evaluates the effectiveness of radiotherapy combined with raltitrexed and irinotecan in treating patients who have metastatic or locally recurrent colorectal cancer that has not responded to fluorouracil. The patients will receive radiotherapy combined with raltitrexed and irinotecan, and then the surgeons will evaluate whether they should receive a surgery.
Recurrent Colorectal Cancer
COMBINATION_PRODUCT: Radiotherapy Combined With Raltitrexed and Irinotecan
ORR(Objective Response Rate) includes CR(Complete Rate) and PR(Partial Rate), 20 weeks
DCR(Disease Control Rate), 20 weeks|PFS(Progression Free Survival), 24 months|the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0, 20 weeks
The study evaluates the effectiveness of radiotherapy combined with raltitrexed and irinotecan in treating patients who have metastatic or locally recurrent colorectal cancer that has not responded to fluorouracil. The patients will receive radiotherapy combined with raltitrexed and irinotecan, and then the surgeons will evaluate whether they should receive a surgery.